Table 1. Baseline characteristics of study patients before and after propensity score analysis.
| Factor | Before Propensity Score Matching | After Propensity Score Matching | ||||
|---|---|---|---|---|---|---|
| Safe group | Vessel group | P Value | Safe group | Vessel group | P Value | |
| Age(y) | 58.7 | 59.4 | 0.542 | 60.28 | 59.43 | 0.574 |
| NO. of men | 233 | 91 | 0.820 | 90 | 91 | 0.798 |
| Tumor size | 2.47 | 2.76 | 0.011 | 2.858 | 2.765 | 0.538 |
| AFP level >200 ng/mL | 47(293) | 30(113) | 0.016 | 22 | 30 | 0.206 |
| Origin of chronic liver disease | 0.905 | 0.961 | ||||
| Hepatitis B virus | 240 | 90 | 87 | 90 | ||
| Hepatitis C virus | 36 | 17 | 20 | 17 | ||
| Other origin | 3 | 1 | 1 | 1 | ||
| None | 14 | 5 | 5 | 5 | ||
| Presence of liver cirrhosis | 0.785 | 0.472 | ||||
| yes | 278 | 107 | 110 | 108 | ||
| no | 15 | 5 | 3 | 5 | ||
| Child-Pugh class | 0.762 | >0.99 | ||||
| Class A | 289 | 111 | 111 | 111 | ||
| Class B | 4 | 2 | 2 | 2 | ||
| NLR before ablation | 2.16 | 2.07 | 0.622 | 2.17 | 2.07 | 0.648 |
| ALT(U/L) | 35.39 | 35.06 | 0.907 | 34.05 | 35.07 | 0.745 |
| PLT (10<sup>9</sup>/L) | 109.02 | 110.01 | 0.908 | 118.3 | 106.01 | 0.000 |
| Follow-up time(mo) | 29.2 | 29.6 | 0.809 | 27.96 | 29.65 | 0.400 |
AFP: α-fetoprotein
NLR: Neutrophil to lymphocyte ratio
ALT: Alanine Aminotransferase
PLT: Platelet